id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-001566-kkaxha7d	Zhang, Mao-Yu	Development of Monoclonal Antibodies in China: Overview and Prospects	2015-02-25		.txt	text/plain	3524	196	44	This paper aims to provide a comprehensive review of mAbs development in China through systematic analysis of drug registry, patent applications, clinical trials, academic publication, and ongoing R&D projects. Over the past three decades, monoclonal antibodies (mAbs) have achieved a dramatic development from scientific tools to powerful human therapeutic agents [1] (see Figure 1 ). Development of this class of therapeutic agents started as early as 1980s but achieved no clinical or commercial success until 2002 when adalimumab became the first human mAb approved by the US Food and Drug Administration (FDA) [14] . R&D of mAbs in China began in the 1980s [16] and the first mAb therapeutic agent (Murine Monoclonal Antibody against Human CD3 Antigen of T Lymphocyte for Injection) was introduced in 1999 [17] . This paper aims to provide a comprehensive review of mAb development in China through systematic analysis of product registry, patent application, clinical trials, academic publication, and ongoing R&D projects.	./cache/cord-001566-kkaxha7d.txt	./txt/cord-001566-kkaxha7d.txt